Christine Hanssen Rinaldo

Prof. Christine Hanssen Rinaldo

1. Department of Microbiology and Infection Control, University hospital of North Norway, N-9038 Tromsø, Norway
+1
orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 June 2008 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
EBE. Bernhoff
E. Bernhoff
TGT. J. Gutteberg
T. J. Gutteberg
KSK. Sandvik
K. Sandvik
HHHans H. Hirsch
Hans H. Hirsch
Christine Hanssen RinaldoChristine Hanssen Rinaldo
Christine Hanssen Rinaldo
The human polyomavirus BK (BKV) causes nephropathy and hemorrhagic cystitis in kidney and bone marrow transplant patients, respectively. The anti-viral cidofovir (CDV) has been used in small case series but the effects on BKV replication are unclear, since polyomaviruses do not encode viral DNA polymerases. We investigated the effects of CDV on BKV(Dunlop) replication in primary human renal proximal tubule epithelial cells (RPTECs). CDV inhibited the generation of viral progeny in a dose-dependent manner yielding a 90% reduction at 40 μg/mL. Early steps such as receptor binding and entry seemed unaffected. Initial large T-antigen transcription and expression were also unaffected, but subsequent intra-cellular BKV DNA replication was reduced by >90%. Late viral mRNA and corresponding protein levels were also 90% reduced. In uninfected RPTECs, CDV 40 μg/mL reduced cellular DNA replication and metabolic activity by 7% and 11% in BrdU and WST-1 assays, respectively. BKV infection increased DNA replication to 142% and metabolic activity to 116%, respectively, which were reduced by CDV 40 μg/mL to levels of uninfected untreated RPTECs. Our results show that CDV inhibits BKV DNA replication downstream of large T-antigen expression and involves significant host cell toxicity. This should be considered in current treatment and drug development.

15 February 2010 in Journal of Virology
Verified
Journal Article
Closed access
PDF file
EBEva Bernhoff
Eva Bernhoff
GTGarth D. Tylden
Garth D. Tylden
LKLars J. Kjerpeseth
Lars J. Kjerpeseth
TGTore J. Gutteberg
Tore J. Gutteberg
HHHans H. Hirsch
Hans H. Hirsch
Christine Hanssen RinaldoChristine Hanssen Rinaldo
Christine Hanssen Rinaldo
The immunomodulatory drug leflunomide is frequently used for treating polyomavirus-associated nephropathy, yet its antiviral mechanism is unclear. We characterized the effects of the active leflunomide metabolite A771726 (LEF-A) on the polyomavirus BK (BKV) life cycle in human renal tubular epithelial cells. LEF-A at 10 μg/ml reduced the extracellular BKV load by 90% (IC90) but with significant host cytostatic effects. BKV genome replication, late protein expression, and virion assembly and release were inhibited with visible disruption of the nuclear replication architecture. Both host cell and antiviral effects were largely reversed by uridine addition, implicating nonspecific pyrimidine depletion as the major anti-BKV mechanism of leflunomide.

19 June 2013 in APMIS
Verified
Journal Article
Closed access
PDF file
Christine Hanssen RinaldoChristine Hanssen Rinaldo
Christine Hanssen Rinaldo
GTGarth D. Tylden
Garth D. Tylden
BSBiswa Nath Sharma
Biswa Nath Sharma

22 September 2009 in Journal of Medical Virology
Verified
Journal Article
Closed access
PDF file
GOGunn‐Hege Olsen
Gunn‐Hege Olsen
HHHans H. Hirsch
Hans H. Hirsch
Christine Hanssen RinaldoChristine Hanssen Rinaldo
Christine Hanssen Rinaldo

1 June 2015 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
GTGarth D. Tylden
Garth D. Tylden
HHHans H. Hirsch
Hans H. Hirsch
Christine Hanssen RinaldoChristine Hanssen Rinaldo
Christine Hanssen Rinaldo
BK polyomavirus (BKPyV)-associated hemorrhagic cystitis (PyVHC) complicates 5 to 15% of allogeneic hematopoietic stem cell transplantations. Targeted antivirals are still unavailable. Brincidofovir (BCV; previously CMX001) has shown inhibitory activity against diverse viruses, including BKPyV in a primary human renal tubule cell culture model of polyomavirus-associated nephropathy. We investigated the effects of BCV in BKPyV-infected and uninfected primary human urothelial cells (HUCs), the target cells of BKPyV in PyVHC. The BCV concentrations causing 50 and 90% reductions (EC50and EC90) in the number of intracellular BKPyV genome equivalents per cell (icBKPyV) were 0.27 μM and 0.59 μM, respectively. At 0.63 μM, BCV reduced viral late gene expression by 90% and halted progeny release. Preinfection treatment for only 24 h reduced icBKPyV similarly to treatment from 2 to 72 h postinfection, while combined pre- and postinfection treatment suppressed icBKPyV completely. After investigating BCV's effects on HUC viability, mean selectivity indices at 50 and 90% inhibition (SI50and SI90) calculated for cellular DNA replication were 2.7 and 2.9, respectively, those for mitochondrial activity were 8.9 and 10.4, those for total ATP were 8.6 and 8.2, and those for membrane integrity were 25.9 and 16.7. The antiviral and cytostatic effects, but less so the cytotoxic effects, were inversely related to cell density. The cytotoxic effects at concentrations of ≥10 μM were rapid and likely related to BCV's lipid moiety. After carefully defining the antiviral, cytostatic, and cytotoxic properties of BCV in HUCs, we conclude that a preemptive or prophylactic approach in PyVHC is likely to give the best results.

17 January 2006 in Journal of Medical Virology
Verified
Journal Article
Closed access
PDF file
GOGunn-Hege Olsen
Gunn-Hege Olsen
PAPer Arne Andresen
Per Arne Andresen
HHHilde Tveitan Hilmarsen
Hilde Tveitan Hilmarsen
OBOla Bjørang
Ola Bjørang
HSHelge Scott
Helge Scott
Christine Hanssen RinaldoChristine Hanssen Rinaldo
Christine Hanssen Rinaldo